Pharma Industry News

A collection of Pharma latest news, analysis and best practices from top business influencers and the world's most trustworthy sources.

globenewswire.com - Pharma Equity Group A/S - Pharma Equity Group consolidated Interim Report 1 January - 30 June 2026
Pharma Equity Group consolidated Interim Report 1 January - 30 June 2026
GlobeNewswire

Consolidated Interim Report 1 January – 30 June 2026 On 14 August 2026, the Board of Directors and the Executive Board of Pharma Equity Group A/S ('PEG', 'The Company' or the 'Group') considered and approved the interim report for the Group…

bloomberg.com - Bastian Benrath-Wright - Swiss Economy Surges Far More Than Forecast, Led by Pharma
Swiss Economy Surges Far More Than Forecast, Led by Pharma
Bloomberg

Swiss growth momentum surged to the fastest pace since 2021, highlighting the economy's resilience to higher energy costs and lingering trade uncertainty. Gross domestic product adjusted for large sport events rose 1.5% in the second quarter from…

thehindu.com - N. Ravi Kumar - U.S. FDA issues warning letter to Aurobindo Pharma's subsidiary Eugia Pharma
U.S. FDA issues warning letter to Aurobindo Pharma's subsidiary Eugia Pharma
The Hindu

A formulation manufacturing facility of Aurobindo Pharma subsidiary near Hyderabad has been issued a warning letter by the U.S. Food and Drug Administration (U.S. FDA). The action on the facility of Eugia Pharma Specialities, the subsidiary…

fool.com - Erin Kennedy - Fidelity Healthcare ETF vs. iShares Pharma Fund: Which Wins?
Fidelity Healthcare ETF vs. iShares Pharma Fund: Which Wins?
The Motley Fool

While Fidelity MSCI Health Care Index ETF (FHLC -0.20%) provides broad healthcare exposure at a very low cost, iShares U.S. Pharmaceuticals ETF (IHE +0.01%) offers a concentrated focus on the domestic pharmaceutical sector for investors seeking…

thehindubusinessline.com - Aurobindo Pharma arm Eugia Pharma's Telangana unit gets warning letter from USFDA
Aurobindo Pharma arm Eugia Pharma's Telangana unit gets warning letter from USFDA
BusinessLine

Aurobindo Pharma on Friday said the US health regulator has issued a warning letter to a formulation manufacturing facility of its arm, Eugia Pharma Specialities Ltd, in Telangana. In May this year the company had stated that the US Food and Drug…

thehindu.com - The Hindu Bureau - India's Q1 pharma exports up 6.8% to $8.1bn; U.S. remains largest export destination
India's Q1 pharma exports up 6.8% to $8.1bn; U.S. remains largest export destination
The Hindu

India's pharmaceutical exports rose 6.8% year-on-year (YoY) to $8.1 billion in the first quarter (Q1) ended June, according to the Pharmaceuticals Export Promotion Council of India (Pharmexcil). Drug formulations and biologicals exports stood at…

thehindubusinessline.com - Natco Pharma's Q1 net down 57% at ₹206 crore; to raise ₹2,000 crore
Natco Pharma's Q1 net down 57% at ₹206 crore; to raise ₹2,000 crore
BusinessLine

Natco Pharma's consolidated net profit declined 57 per cent at ₹206 crore in the first quarter ended June 30, 2026, compared to ₹480 crore for the corresponding quarter last year. The total revenue of the Hyderabad based company stood…

247wallst.com - Trey Thoelcke - Wave Life Sciences: A $1 Billion RNA-Medicine Bargain Ripe for Pharma Takeover
Wave Life Sciences: A $1 Billion RNA-Medicine Bargain Ripe for Pharma Takeover
24/7 Wall St

WVE sits 69% below its yearly high at a $1 billion market cap, with obesity drug WVE-007 showing visceral fat cuts and muscle preservation. GSK leads plausible acquirers given its existing WVE-006 partnership, while LLY could attach WVE-007 to…

marketbeat.com - Ascendis Pharma A/S Q2 Earnings Call Highlights
Ascendis Pharma A/S Q2 Earnings Call Highlights
MarketBeat

Can BioMarin Stock Live Up to Wall Street's High Expectations? Ascendis Pharma A/ S NASDAQ: ASND reported second-quarter 2026 total revenue of EUR 339 million, including EUR 315 million in product revenue, as demand for its three commercial…

globenewswire.com - Pharma Equity Group A/S - Correction to Consolidated Interim Report 1 January - 30 June 2026
Correction to Consolidated Interim Report 1 January - 30 June 2026
GlobeNewswire

Correction to Consolidated Interim Report 1 January – 30 June 2026 The previous announcement with the half year report was missing the report. The announcement is re-published, including the report. On 14 August 2026, the Board of Directors…

leftfieldinvesting.substack.com - Left - Haypp Group, Terravest Industries, Zedcor Inc, Delcath, and Moberg Pharma report
Haypp Group, Terravest Industries, Zedcor Inc, Delcath, and Moberg Pharma report
Left's Newsletter

When Haypp Group decides to prioritize earnings instead of growth, they will make a lot of money. They are obviously still trying to grow as fast as they can. Ironically if they stay in this growth state forever the shares would probably continue…

seekingalpha.com - Galzus Research - Kyverna Therapeutics: Market Holding Flat Despite Progress To Approval (NASDAQ:KYTX)
Kyverna Therapeutics: Market Holding Flat Despite Progress To Approval (NASDAQ:KYTX)
Seeking Alpha

Kyverna Therapeutics, Inc. remains a compelling Buy as it advances mivocabtagene autoleucel for autoimmune diseases, targeting first approval in stiff person syndrome. Updated KYSA-8 trial data show all 26 patients remained off chronic…

mumsnet.com - US government report reveals mass insurance fraud in the gender change industry
US government report reveals mass insurance fraud in the gender change industry
Mumsnet

Please or to access all these features Feminism: Sex and gender discussions Big news. The extent of this is appalling, but not surprising. With WPATH admitting its ideas have no basis the foundations behind the huge gender medical industry in the…

fool.com - Thomas Niel - Is the Reported $400 Billion AstraZeneca-Bristol Myers Squibb Megamerger a Slam Dunk -- or a Disaster Waiting to Happen?
Is the Reported $400 Billion AstraZeneca-Bristol Myers Squibb Megamerger a Slam Dunk -- or a Disaster Waiting to Happen?
The Motley Fool

In recent weeks, two pharmaceutical stocks, AstraZeneca (AZN -0.80%) and Bristol Myers Squibb (BMY +1.49%), have become the subject of merger rumors. At the start of the month, the Financial Times dropped a potential bombshell when, in an exclusive…

fool.com - Ben Gran - Vanguard Is Bullish on Developed Markets Outside the U.S. -- But How Can You Buy Them? These 2 ETFs Can Help.
Vanguard Is Bullish on Developed Markets Outside the U.S. -- But How Can You Buy Them? These 2 ETFs Can Help.
The Motley Fool

Which stocks will be the big winners of the artificial intelligence (AI) boom? Until recently, many investors might have assumed that major U.S. growth stocks, tech names, and AI hyperscalers would be the biggest winners -- after all, those…

Receive a Daily briefing on Pharma Industry News

Get Started